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Diabetes mellitus is a group of metabolic disorder 
characterized by hyperglycemia either due to deficiency of 
insulin production or resistance of organs to the effect of 
normal amount of insulin or both.1 In healthy individuals 
after taking meals, according to the blood glucose 
concentration appropriate amount of insulin is produced by 
the pancreas and this insulin transports glucose from blood 
into the cells. In diabetic individual, either little or no insulin 
is produced by the pancreas, or the cells do not give 
appropriate response to the produced insulin. This insulin 
dysfunction leads to decreased synthesis and increased 
degradation of glycogen, protein and fat in the body, 
ultimately causing hyperglycemia and overflow of glucose 
into urine.2 Characteristic symptoms of diabetes are thirst, 
polyuria, weight loss and blurring of vision. Most severe 
form is characterized by ketoacidosis or non ketotic 
hyperosmolar coma, ultimately leading to stupor, coma and 
death. Chronic hyperglycemia develops pathological and 
functional changes characterized by retinopathy, 
nephropathy and neuropathy. Risk of cardiovascular, 
peripheral vascular and cerebrovascular diseases is also 
common in chronic state.3   
Diabetes is a universal health issue. Its prevalence is 
continuously increasing worldwide. Estimated rise in world 
prevalence of diabetes is 6.4% to 7.7% from 2010 to 2030. 
Different factors like population growth, ageing and 
sedentary life styles are responsible for continuously 
increasing burden of diabetes in developing countries. In 
Pakistan in 2010 about 7.1 million people were suffering 
with diabetes. This number is expected to rise up to 13.8 
million by 2030.4  On the basis of etiology diabetes can be 
classified into various types (Table 1). Among all of them 
most important are type I, type II and gestational diabetes 
mellitus. 
Type 1 diabetes 
Type 1 diabetes was previously known as insulin dependent 
diabetes or juvenile onset diabetes. Being an autoimmune 
disease, it is characterized by destruction of insulin 
producing beta cells in the pancreas by the body’s own 
immune system. In turn insulin production is either 
decreased or completely lost depending upon the extent of 
pancreatic injury.5 Type 1 diabetes, although most 
commonly encountered during childhood and adolescence, 
can also be diagnosed as late as the 8th or 9th decade of life.6 
Rate of destruction of pancreatic beta cells varies from very 
high to low among different age groups. Most frequently in 
children, but also in some adults, rapid progressive beta cells 
destruction is commonly manifested by absolute insulin 
deficiency. On the other hand, a slowly progressive form is 
usually observed in adults and is sometimes known as 
“latent autoimmune diabetes in adults (LADA)”.7,8  
Genetic inclination and environmental factors play an 
important role in its pathogenesis.5 Some individuals who 
present with permanent hypoinsulinemia, have tendency to 
develop ketoacidosis, but have no evidence of 
autoimmunity, are labeled as type 1 idiopathic diabetes.9 In 
individuals with type 1 diabetes process of beta cells 
destruction usually starts very early, but symptoms may 
appear late. That is why in 85-90% of such individuals when 
first diagnosed with fasting hyperglycemia, markers of 
immune destruction including islet cell autoantibodies 
and/or autoantibodies to insulin, and autoantibodies to 
glutamic acid decarboxylase (GAD) will also be detected in 
their blood.10 Role of HLA, with linkage to DQA and DQB 
genes and influence by DRB genes is also evident in type 1 
diabetes.5 Children usually present with severe symptoms, 
marked hyperglycemia or ketoacidosis as the first 
manifestation of the disease.11  While some individuals 
present with moderate hyperglycemia and in the presence of 
different contributory factors like infection or stress this 
moderate form may deteriorate into severe hyperglycemia or 
ketoacidosis. Adults having type 1 diabetes usually present 
with less severe symptoms due to residual beta cell 
functions. These individuals develop ketoacidosis after 
many years of diagnosis when beta cells completely lose 
their function leading to little or no insulin production as 
manifested by low or undetectable levels of plasma C-
peptide.7,12  Patients with type 1 diabetes may also suffer 
from other autoimmune disorders like Grave’s disease, 
Hashimoto’s thyroiditis and Addison’s disease.13   
Type 2 diabetes 
Type 2 diabetes was previously recognized as non insulin 
dependent diabetes or adult onset diabetes. It is the most 
common form of diabetes characterized by relative insulin 
deficiency. In individuals presenting with type 2 diabetes, at 
the time of diagnosis the production of insulin from 
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pancreas is sufficient, but ability of the body to utilize this 
insulin decreases; the condition is called insulin resistance 
that leads to hyperglycemia. Over the subsequent years, the 
function of beta cells also decreases gradually; concentration 
of glucose in blood further enhances and body is no more 
able to do efficient use of its main source of fuel.14,15  
Initially hyperglycemia is not so severe as to produce 
considerable symptoms; therefore, the patients are usually 
diagnosed after many years. Long term risk of micro- and 
macrovascular complications is greater in such patients.16 
Ketoacidosis rarely occurs in this type of diabetes. If present 
it usually occurs in the presence of infection or some other 
illness.5   
This form of diabetes is most often associated with older 
age, obesity and other risk factors (Table 2). About 80 
percent of people with type 2 diabetes are overweight or 
obese.17 Obesity itself is responsible for insulin resistance in 
type 2 diabetes. Due to the polygenic nature, type 2 diabetes 
may involve polymorphisms in multiple genes that encode 
the proteins involved in insulin signaling, insulin secretion 
and intermediary metabolism.2   
Gestational diabetes 
Gestational diabetes is defined as carbohydrate intolerance 
with onset or first recognition during pregnancy 
(approximately after 24 weeks of gestation). In pregnancy, 
up to first half of second trimester glucose levels, both in 
fasting and postprandial states are usually lower than such 
levels in normal non pregnant women. Women having 
increased glucose concentration during this time are usually 
labelled as having overt diabetes mellitus, but not the 
gestational diabetes. Risk of gestational diabetes in women 
increases with increasing age, in those who have previous 
history of glucose intolerance, and those who have history 
of ‘large for gestational age babies’, in different ethnic 
groups. Women having these risk factors should be screened 
during the first trimester in order to rule out the previously 
undiagnosed diabetes mellitus. Gestational diabetes occurs 
due to placental hormone changes that affect the insulin 
functions. Gestational diabetes mellitus usually disappears 
after the birth of baby, but there are greater chances of 
developing diabetes mellitus type 2 within next few years. 
Maintenance of body weight and appropriate physical 
activity may help in reducing this risk.3,17   
Other specific types 
Other specific types of diabetes, which are relatively less 
common aredepicted in table 1.5  
Pre diabetes 
Pre diabetes is defined as a condition in which the blood 
glucose concentration is greater than normal but lesser than 
the levels essential for the diagnosis of diabetes mellitus. 
This encompasses the conditions of impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT) representing 
glucose regulation abnormalities during fasting and post-
prandial state, respectively. Due to insulin resistance, 
pancreatic beta cells initially undergo compensatory state 
and produce larger amount of insulin than normal. This 
higher concentration of insulin tries to overcome the 
increase demand and ultimately maintains the blood glucose 
concentration some way intermediate between normal 
glucose levels and diabetic glucose level.3,17    
Hemoglobin A1C  
Hemoglobin A1C (HbA1C) is stable glycosylated 
hemoglobin. It shows the average blood glucose level of last 
2-3 months (120 days life span of erythrocytes). It gives a 
percentage that indicates the risk of development, diagnosis 
and previous 2-3 months control of diabetes. In certain 
conditions HbA1C is not considered appropriate for 
diagnosis of diabetes. These conditions include18   
1. ALL children and young people 
2. Patients of any age suspected of having Type 1 diabetes 
or type 2 diabetes with a severe insulin deficiency (glycemic 
variability) 
3. Patients with symptoms of diabetes for less than 2 
months 
4. Patients at high diabetes risk who are acutely ill (e.g. 
those requiring hospital admission) 
5. Patients taking medication (e.g. steroids, antipsychotics) 
that may cause rapid glucose rise  
6. Patients with acute pancreatic damage, including 
pancreatic surgery 
7. Pregnancy 
8. Presence of genetic, haematologic and illness-related 
factors that influence  HbA1C and its measurement 
Screening for Diabetes Mellitus 
Because of the acute onset of symptoms, most cases of type 
1 diabetes are detected soon after symptoms develop; 
screening is therefore not so important in this type of 
diabetes. According to some studies analysis of islet 
autoantibodies in some high risk individuals like those with 
previous transient hyperglycemia, or having family history 
of type 1 diabetes may be appropriate. But screening for 
type 1 diabetes in asymptomatic low risk individuals is not 
currently recommended.20 On the other hand, in case of type 
2 diabetes, situation is quite different. Individuals usually 
present with clinical signs and symptoms several years after 
the commencement of the disease process.  Sometimes the 
complications may develop in individuals several years prior 
to the clinical diagnosis. Therefore screening is considered 
necessary in type 2 diabetes mellitus to identify 
asymptomatic individuals who are prone to develop diabetes 
or pre diabetes. Due to the increased chances of diabetes 
type 2 in children, screening is also considered important in 
them.19,20   
Screening criteria in children for type 2 diabetes 
Screening for type 2 diabetes is recommended, if a child is 
overweight with BMI >85th percentile for age and sex, 
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 Table 1. Classification of diabetes mellitus5 
1. Type 1 diabetes 
2. Type 2 diabetes 
3. Genetic defects of β-cell function 
a. Chromosome 20, HNF-4 a (MODY 1) 
b. Chromosome 7, glucokinase (MODY 2) 
c. Chromosome 12, HNF-1 a (MODY 3 ) 
d. Chromosome 13, insulin promoter factor-1  
( IPF-1; MODY 4 ) 
e. Chromosome 17, HNF-1 b (MODY 5 ) 
f. Chromosome 2 , NeuroD1 (MODY 6) 
g. Mitochondrial DNA and others 
4. Genetic defects in insulin processing or insulin 
action 
a. Type A  insulin resistance 
b.  Leprechaunism 
c.  Rabson-Mendenhall syndrome 
d.  Lipoatrophic diabetes and others 
5. Exocrine pancreatic defects 
a. Pancreatitis 
b. Trauma/pancreatectomy 
c.  Neoplasia  
d. Cystic fibrosis 
e.  Hemochromatosis and others 
6. Endocrinopathies 
a. Acromegaly  
b. Cushing’s syndrome  
c. Glucagonoma 
d.  Pheochromocytoma 
e.  Hyperthyroidism  and others 
7. Infections 
a. Congenital rubella 
b. Cytomegalo virus and others 
8. Drugs 
a. Nicotinic acid  
b. Glucocorticoid 
c. Thyroid hormone 
d. Diazoxide 
e. β -adrenergic agonists 
f. Thiazides 
g. Dilantin 
h. γ- Interferon and others 
9. Genetic syndromes associated with diabetes 
a. Down syndrome 
b.  Klinefelter syndrome 
c.  Turner syndrome 
d.  Friedreich ataxia and others 
10. Gestational diabetes mellitus 
weight for height >85th percentile or weight >120% of ideal 
(50th percentile for height) and presents with any two of the 
following listed risk factors: 
 Positive family history of type 2 diabetes in first or 
second degree relative(s) 
 Certain races or ethnicities like Asian/Pacific islanders, 
American Indian, African-Americans, and Hispanics.  
Table 2: Risk factors associated with type 2 diabetes 
mellitus 
 Family history of diabetes (i.e. parents or siblings have 
diabetes) 
 Overweight (BMI > 25 kg/m2) 
 Habitual physical activity 
 Race/ethnicity (e.g. African-American, Hispanic-
American, Native Americans, Asian-Americans, and 
Pacific Islanders) 
 Previously identified IFG or IGT or HbA1C 5.7-6.4% 
 Hypertension (>140/90 mmHg in adults) 
 HDL cholesterol <35 md/dl (0.90 mmol/l) and/or a 
triglyceride level >250 mg/dl (2.82 mmol/l) 
 History of GDM or delivery of a baby weighing >9lbs 
 Polycystic ovarian syndrome or acanthosis nigricans 
 History of vascular disease 
 
Table 3: Glucose levels enlightening normal condition, 
increase risk and diabetes mellitus 
 Glucose level mg/dl (mmol/l) HbA1c 
(%) Fasting Random OGTT
Euglycemia 
(normal glucose 
levels) 
<100 
(5.6) 
<200  
(11.1) 
<140 
(7.8) 
<5.7 
Increased risk for 
diabetes 
100-125 
(5.6-6.9) 
( IFG) 
 
- 
140-199 
(7.8-11) 
( IGT) 
5.7-6.4 
(Pre 
diabetic) 
Diabetes mellitus ≥126 
(7.0) 
≥200 
(11.1) 
≥200 
(11.1) 
≥6.5% 
 
 History of hypertension, dyslipidemia, polycystic ovary 
syndrome or acanthosis nigricans (conditions associated 
with signs of  insulin resistance)  
 Maternal history of diabetes or gestational diabetes 
mellitus 
Table 4: Criteria for diagnosis of diabetes mellitus 
1. HbA1C ≥6.5%, done in laboratory using a National 
Glycohemoglobin Standardization Program (NGSP) 
certified method and standardization to Diabetes 
Control and Complications Trial (DCCT) reference 
assay 
2. Fasting plasma glucose (FPG) ≥126mg/dl (7.0 mmol/l). 
fasting is described as no calorie intake for at least 8 
hours, only water is allowed 
3. During an OGTT, 2 hours plasma glucose ≥200mg/dl 
(11.1mmol/l) as described by world health 
organization. 
4. A random plasma glucose concentration of ≥ 200 
mg/dl (11.1 mmol/l) with classical sign and symptoms 
of diabetes or with hyperglycemic crises 
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Screening should start at age of 10 years or at the start of 
puberty if puberty occurs at early age and it should be 
repeated after every two years. Fasting plasma glucose is 
most preferable method of screening.21   
Screening criteria in adults for type 2 diabetes 
1. Screening should be started in adults ≥ 45 years of age, 
especially if they have BMI ≥25 kg/m2. If results are 
normal, the screening should be repeated at an interval 
of 3 years.  
2. Adults should be screened early (< 45 years of age) and 
more frequently if they are overweight (BMI ≥25 
kg/m2)  and have additional risk factors (Table 2)  
3. For screening, either fasting plasma glucose (FPG) or 2 
hour OGTT (75 gm glucose load) or HbA1C or all are 
considered suitable. 5,21 (Table 3)  
Diagnosis of Diabetes Mellitus 
Symptoms of diabetes mellitus include fatigue, nausea, 
frequent urination/polyuria, excessive thirst, obesity (mostly 
in type 2 diabetes), unusual weight loss, blurred vision, 
frequent infections, slow healing of wounds or sores. 
Sometimes no specific symptoms are present.17 Although 
glucose analysis can be done in whole blood or serum but 
the most preferable sample is plasma. In case of normal 
hematocrit, glucose concentration is about 11% more in 
plasma as compared to whole blood. In whole blood, 
glucose decreases due to glycolysis. Such decreases in 
glucose concentration can miss the diagnosis of diabetes in a 
large proportion of population who have glucose 
concentrations near the cut points for diagnosis. In plasma 
and serum glucose variation is only about 1-2%.22-24 
However, immediate centrifugation in case of plasma 
prevents glycolysis while in case of serum,  sample has to 
clot first and thus causes loss of glucose due to glycolysis.5   
Diagnostic criteria of diabetes mellitus are mentioned in 
table 4. In the absence of unequivocal hyperglycemia, 
criteria 1-3 should be confirmed by repeat testing. For 
example, if only one test like HbA1C or FPG or OGTT is 
performed, then in order to confirm the diagnosis, the same 
test should be repeated.  Sometimes, if the results of FPG 
are <7 mmol/l, but still there is strong suspicion of diabetes, 
then an OGTT should be performed. If the results of two 
different tests of same patient are provided, and both are 
above the diagnostic values of diabetes mellitus, then the 
diagnosis of diabetes is confirmed and there is no need to 
further repeat the test.  In cases where the results of two 
tests in same patient are opposite to each other (one above 
the diagnostic value of diabetes while second one in normal 
range), then the test whose result is above the diagnostic cut 
point should be repeated. The diagnosis in such a situation 
should be confirmed on the basis of repeat test results. 
Considering the pre-analytical and analytical variabilities, 
sometimes in contrast to the first test result, the repeat test 
may show a value within the reference range. This is most 
common in case of OGTT than FPG and least common in 
case of HbA1C. In such a situation, patient should be 
followed closely, and it is recommended that the test should 
be repeated within 3-6 months.5 
Prognosis/Control of Diabetes 
HbA1C is a widely used method to calculate the last 2-3 
months diabetic control. In diabetics, it should be 
maintained at or below 7%. As the value of HbA1C 
increases, there will be more risk of developing 
microvascular and to lesser extent macrovascular 
complications.5,20 It is generally recommended that HbA1C 
should be repeated at an interval of six months in patients 
who respond well to their treatment and have good glucose 
control. If diabetics have a bad glycemic control or if the 
anti-diabetic medication is to be changed, the test should be 
repeated at an interval of three months.20     
Oral glucose tolerance test (OGTT) 
Indications: Equivocal blood glucose levels, pregnancy or 
epidemiological studies. 
Preparation:  Patient should be advised to take unrestricted 
diet (greater than 150 g of carbohydrate daily) and maintain 
usual physical activity at least for three days before the test. 
Reasonable (30-50g) carbohydrate containing meal should 
be consumed on the evening before the test. The test should 
be preceded by an overnight fast of 8-14 hours, during 
which water may be allowed. Smoking is not permitted 
during the test. The presence of factors that influence 
interpretation of the results of the test must be recorded (e.g. 
medications, inactivity, infection, etc.). 
Procedure: After collection of the fasting blood sample, the 
subject should drink 75 g of anhydrous glucose or 82.5 g of 
glucose monohydrate (or partial hydrolysates of starch of 
the equivalent carbohydrate content) in 250-300 ml of water 
over a course of 5 minutes. For children, the test load should 
be 1.75 g of glucose per kg body weight up to a total of 75 g 
of glucose. Timing of the test is from the start of the drink. 
Blood samples must be collected 2 hours after the test load. 
Unless the glucose concentration can be determined 
immediately, the blood sample should be collected in a tube 
containing sodium fluoride (6 mg/ml whole blood) and 
immediately centrifuged to separate the plasma; the plasma 
should be frozen until the glucose concentration can be 
estimated.3 Results are interpreted according to table 3. 
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